NUVB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

32.58M

+470.48%

-0.104

-30.37%

30.80M

+898.64%

-0.196

+22.5%

40.18M

+731.35%

-0.170

-0%

Estimates Revision

The market is revising Upward the revenue expectations for Nuvation Bio Inc. (NUVB) for FY2025, with the revenue forecasts being adjusted by 47.14% over the past three months. During the same period, the stock price has changed by 159.02%.

Revenue Estimates for FY2025

Revise Upward

+47.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.84%

In Past 3 Month

Stock Price

Go Up

+159.02%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 10.38 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.470

Low

8.00

Averages

10.38

High

12.00

Current: 8.470

Low

8.00

Averages

10.38

High

12.00

H.C. Wainwright

Buy

maintain

$10 -> $18

2025-12-11

New

Reason

H.C. Wainwright

Price Target

$10 -> $18

2025-12-11

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Nuvation Bio to $18 from $10 and keeps a Buy rating on the shares. The firm cites its revised Ibtrozi revenue forecasts for the target increase.

Clear Street

Buy

maintain

$12

2025-11-26

Reason

Clear Street

Price Target

$12

2025-11-26

maintain

Buy

Reason

Clear Street reiterates a Buy rating and $12 price target on shares of Nuvation Bio after the company announced that it has discontinued development of NUV-1511, its lead DDC for advanced solid tumors. Clear Street does not view this as thesis-changing, telling investors in a research note that taletrectinib and safusidenib are distinct assets and that it expects blockbuster potential from taletrectinib and safusidenib's success, with pivotal trial completion in 2029, offers incremental upside to the firm's model.

Truist

Buy

initiated

$11

2025-11-24

Reason

Truist

Price Target

$11

2025-11-24

initiated

Buy

Reason

Truist initiated coverage of Nuvation Bio with a Buy rating and $11 price target. Ibtrozi's FDA approvoal positions Nuvation Bio as a commercial-stage player in precision oncology, notes the analyst, who likes the launch set-up "led by a proven team" and supported by Ibtrozi's competitive profile in ROS1 non-small cell lung cancer.

Citizens JMP

Outperform

maintain

$8 -> $10

2025-11-20

Reason

Citizens JMP

Price Target

$8 -> $10

2025-11-20

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Nuvation Bio to $10 from $8 and keeps an Outperform rating on the shares. Safusidenib, in a Phase 2 Japanese glioma study, significantly outperformed based on overall response rate, compared to the Phase 3 INDIGO study of vorasidenib, the analyst tells investors in a research note. Nuvation Bio plans to move forward with safusidenib in a higher-grade glioma setting, which is a sensible path, Citizens says.

Wedbush

NULL -> Outperform

maintain

$7 -> $11

2025-11-19

Reason

Wedbush

Price Target

$7 -> $11

2025-11-19

maintain

NULL -> Outperform

Reason

Wedbush raised the firm's price target on Nuvation Bio to $11 from $7 and keeps an Outperform rating on the shares.

B. Riley

Buy

initiated

$12

2025-11-19

Reason

B. Riley

Price Target

$12

2025-11-19

initiated

Buy

Reason

B. Riley initiated coverage of Nuvation Bio with a Buy rating and $12 price target. The firm cites the company's positive commercial revenue ramp of its lead drug Ibtrozi within mutation-defined lung cancer for the Buy rating. The drug's "class-leading attributes are supporting robust early launch metrics," the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Nuvation Bio Inc (NUVB.N) is -14.89, compared to its 5-year average forward P/E of -8.89. For a more detailed relative valuation and DCF analysis to assess Nuvation Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.89

Current PE

-14.89

Overvalued PE

-1.27

Undervalued PE

-16.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.51

Current PS

0.00

Overvalued PS

230.01

Undervalued PS

-139.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 287.18% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 287.18% over the last month.

Sold

Bought

NUVB News & Events

Events Timeline

No data

News

4.0

12-15NASDAQ.COM

Nuvation Bio (NUVB) Receives Upgrade to Buy: Key Information You Need to Know

8.5

12-07PRnewswire

Innovent's Seven Innovative Drugs Included in 2025 NRDL

8.5

12-07Newsfilter

Innovent Biologics Secures Inclusion of Seven Innovative Drugs in 2025 NRDL

People Also Watch

Frequently Asked Questions

What is Nuvation Bio Inc (NUVB) stock price today?

The current price of NUVB is 8.47 USD — it has decreased -0.47 % in the last trading day.

What is Nuvation Bio Inc (NUVB)'s business?

Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

What is the price predicton of NUVB Stock?

What is Nuvation Bio Inc (NUVB)'s revenue for the last quarter?

Nuvation Bio Inc revenue for the last quarter amounts to 13.12M USD, increased 1704.68 % YoY.

What is Nuvation Bio Inc (NUVB)'s earnings per share (EPS) for the last quarter?

Nuvation Bio Inc. EPS for the last quarter amounts to -0.16 USD, increased 6.67 % YoY.

What changes have occurred in the market's expectations for Nuvation Bio Inc (NUVB)'s fundamentals?

How many employees does Nuvation Bio Inc (NUVB). have?

Nuvation Bio Inc (NUVB) has 220 emplpoyees as of December 16 2025.

What is Nuvation Bio Inc (NUVB) market cap?

Today NUVB has the market capitalization of 2.92B USD.